Furthermore, trabedersen (also known as AP12009 or OT101) is a synthetic antisense oligodeoxynucleotide specific for TGFβ2 mRNA with the orphan drug designation by FDA that had gone through clinical trials in pancreatic and colorectal neoplasms, melanoma (NCT00844064), anaplastic astrocytoma, and glioblastoma (NCT00761280 and NCT00431561) [21] in a period prior to that considered in this review. This evidence concerns the gene TGFB2 and melanoma.